SK Biopharmaceuticals and its U.S. R&D subsidiary, Proteovant Therapeutics, presented data showing that selectively degrading the epigenetic protein p300, with minimal impact on its paralog CBP, results in suppression of androgen receptor signaling and inhibition of tumor growth in a mouse model of androgen receptor (AR) positive prostate cancer. Findings are being presented at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston. The AACR-NCI-EORTC Conference attracts researchers from around the world to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.

Today's presentation is the second in a series of important meetings at which the Proteovant team is sharing research findings that show potential best- and first-in-class protein degraders. AACR-NCI-E ORTC International Conference on Molecular Target and Cancer Therapeutics: Title: Discovery and characterization of a p300-selective degrader demonstrates potent anti-tumor activity in preclinical models of prostate cancer; Presenter: Mike Russell, Ph.D. Director of Biology; Date/Time: Thursday, October 12, 12:30-4:00pm. About Proteovant Therape therape exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the treatment of patients with life-altering diseases.

Protein degradation harnesses the human body's innate cellular machinery by way of the UPS to identify and mark disease causing proteins for destruction. This promising approach provides the opportunity to target proteins of interest, many of which were previously considered undruggable. Proteovant integrates its AI enabled target ID platform, degrader drug hunting expertise, and MOPED??

molecular glue screening platform to advance novel protein degraders. As of August 11, 2023, Proteovant Theraputics is part of SK Group, one of the largest conglomerates in Korea and one of TIME's 100 Most Influential Companies of 2023.